How much funding has CorFlow raised?

CorFlow has raised $60.4M in total funding, most recently a Series B round.

Who are CorFlow's investors?

CorFlow's investors include Broadview Ventures, Panakes Partners, Wellington Management, Korys, Mérieux Equity Partners, KOFA Healthcare.

Where is CorFlow headquartered?

CorFlow is headquartered in Baar, Switzerland.

What industry is CorFlow in?

CorFlow operates in Biotech, Healthcare.

CorFlow

Baar, Switzerland · Founded 2016 · $60.4M raised

Biotech

Healthcare

Headquarters: Baar
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: corflow.com
Total Funding: $60.4M
Last Round: $48.0M Series BSep 2024
Rounds: 3

About

CorFlow Therapeutics AG is a clinical-stage medical device company founded in 2016 and headquartered in Baar, Switzerland, with offices also in Bern. The company is developing the CoFI (Controlled Flow Infusion) System, the first device designed to diagnose and treat microvascular obstruction (MVO) in real time during percutaneous coronary intervention (PCI) for STEMI heart attack patients. MVO — the blockage of small heart blood vessels following a heart attack — affects up to 60% of acute heart attack patients and is the most powerful predictor of re-hospitalization with heart failure. CorFlow's CoFI System received FDA Breakthrough Device Designation in 2019, completed the first-in-human MOCA I trial in 2024, and received FDA approval to proceed with the MOCA II pivotal trial in 2025. In September 2024, the company closed a €44 million (~$48.5M) Series B financing round. CorFlow is CEO-led by Paul Mead and has been backed by angel investors, venture capital, and Swiss government innovation grants.

Summary

CorFlow is a Biotech company based in Baar, Switzerland, founded in 2016. It has raised $60.4M in total across 3 rounds, most recently a $48.0M Series B round in Sep 2024. Investors include Broadview Ventures, Panakes Partners and Wellington Management.

LinkedIn X (Twitter)